Genetics	NNP	3
Institute	NNP	3
Inc.	NNP	7
,	,	7
Cambridge	NNP	7
,	,	7
Mass.	NNP	9
,	,	7
said	VBD	0
it	PRP	11
was	VBD	9
awarded	VBN	11
U.S.	NNP	14
patents	NNS	12
for	IN	12
Interleukin-3	NN	20
and	CC	20
bone	NN	20
morphogenetic	JJ	20
protein	NN	15
.	.	9

The	DT	2
patent	NN	5
for	IN	2
Interleukin-3	NN	3
covers	VBZ	0
materials	NNS	8
and	CC	8
methods	NNS	5
used	VBN	8
to	TO	11
make	VB	9
the	DT	17
human	JJ	17
blood	NN	17
cell	NN	17
growth	NN	17
factor	NN	11
via	IN	11
recombinant	JJ	21
DNA	NNP	21
technology	NN	18
.	.	5

Sandoz	NNP	2
Ltd.	NNP	3
has	VBZ	0
licensed	VBN	3
certain	JJ	9
manufacturing	NN	9
and	CC	9
marketing	NN	9
rights	NNS	4
for	IN	9
Interleukin-3	NN	10
from	IN	4
Genetics	NNP	14
Institute	NNP	12
and	CC	3
is	VBZ	3
conducting	VBG	16
preclinical	JJ	19
studies	NNS	17
with	IN	17
it	PRP	20
.	.	3

Interleukin-3	NN	2
may	MD	24
help	VB	2
in	IN	3
treating	VBG	4
blood	NN	8
cell	NN	8
deficiencies	NNS	5
associated	VBN	8
with	IN	9
cancer	NN	12
treatment	NN	20
,	,	20
bone	NN	16
marrow	NN	16
transplants	NNS	20
and	CC	20
other	JJ	20
blood-cell	NN	20
disorders	NNS	10
,	,	24
Genetics	NNP	23
Institute	NNP	24
said	VBD	0
.	.	24

The	DT	3
second	JJ	3
patent	NN	4
describes	VBZ	0
bone	NN	7
morphogenetic	JJ	7
protein-1	NN	10
,	,	10
a	DT	10
substance	NN	4
that	WDT	10
can	MD	11
induce	VB	12
formation	NN	13
of	IN	14
new	JJ	17
cartilage	NN	15
.	.	4

The	DT	2
patent	NN	3
covers	VBZ	21
BMP-1	NN	6
type	NN	6
proteins	NNS	11
and	CC	11
pharmaceutical	JJ	11
compositions	NNS	11
and	CC	11
methods	NNS	3
for	IN	11
treating	VBG	12
bone	NN	17
or	CC	17
cartilage	NN	17
defects	NNS	13
,	,	21
Genetics	NNP	20
Institute	NNP	21
said	VBD	0
.	.	21

The	DT	2
company	NN	3
added	VBD	25
that	IN	3
it	PRP	6
has	VBZ	4
filed	VBN	6
patent	NN	9
applications	NNS	7
``	``	7
on	IN	7
a	DT	14
large	JJ	14
number	NN	11
of	IN	14
different	JJ	18
BMP	NN	18
proteins	NNS	15
''	''	7
and	CC	25
the	DT	22
patent	NN	25
on	IN	22
BMP-1	NN	23
is	VBZ	0
the	DT	27
first	JJ	25
it	PRP	29
has	VBZ	27
received	VBN	29
.	.	25

BMP	NN	2
products	NNS	3
may	MD	24
be	VB	3
useful	JJ	4
in	IN	4
fracture	NN	8
healing	NN	6
and	CC	6
in	IN	6
treating	VBG	10
bone	NN	13
loss	NN	11
associated	VBN	13
with	IN	14
periodontal	JJ	17
disease	NN	20
and	CC	20
certain	JJ	20
cancers	NNS	15
,	,	24
the	DT	23
company	NN	24
said	VBD	0
.	.	24
